Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Operations: 2015-2024

Historic Cash from Operations for Corvus Pharmaceuticals (CRVS) over the last 10 years, with Dec 2024 value amounting to -$25.4 million.

  • Corvus Pharmaceuticals' Cash from Operations fell 51.34% to -$9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.1 million, marking a year-over-year decrease of 44.95%. This contributed to the annual value of -$25.4 million for FY2024, which is 6.22% down from last year.
  • According to the latest figures from FY2024, Corvus Pharmaceuticals' Cash from Operations is -$25.4 million, which was down 6.22% from -$23.9 million recorded in FY2023.
  • In the past 5 years, Corvus Pharmaceuticals' Cash from Operations ranged from a high of -$23.9 million in FY2023 and a low of -$36.7 million during FY2021.
  • In the last 3 years, Corvus Pharmaceuticals' Cash from Operations had a median value of -$25.4 million in 2024 and averaged -$25.5 million.
  • Per our database at Business Quant, Corvus Pharmaceuticals' Cash from Operations rose by 26.40% in 2022 and then decreased by 6.22% in 2024.
  • Over the past 5 years, Corvus Pharmaceuticals' Cash from Operations (Yearly) stood at -$34.8 million in 2020, then decreased by 5.57% to -$36.7 million in 2021, then climbed by 26.40% to -$27.0 million in 2022, then grew by 11.43% to -$23.9 million in 2023, then dropped by 6.22% to -$25.4 million in 2024.